Hotgen Biotech Reaches Strategic Cooperation with JOINN Biologics and JOINN Laboratories to Build a Full-Chain Innovative Drug R&D Service System

Recently, Beijing Sungen Biomedical Technology Co., Ltd., a strategically controlled company of Beijing Hotgen Biotech Co., Ltd. and referred to as Sungen Biomedical, together with Beijing JOINN Biologics Co., Ltd. and JOINN Laboratories (China) Co., Ltd., jointly announced the formal signing of a strategic cooperation agreement.

This cooperation aims to integrate the strengths and resources of all parties. The three parties will carry out deep cooperation in innovative drug R&D and evaluation, resource sharing, information exchange, and other areas. Together, they will build a full-chain R&D service system covering early-stage discovery through commercial production.

According to the agreement, the three parties will establish a long-term and stable strategic partnership. By complementing each other's professional strengths, they aim to improve project execution efficiency, shorten R&D timelines, and increase the first-time success rate of new drug registration.

As a one-stop biologics CDMO company, JOINN Biologics will participate in project discussions during the early drug discovery stage and provide a complete set of CMC services that meet IND application requirements. As a leading non-clinical CRO company in China, JOINN Laboratories will provide support during druggability research, systematic evaluation, and other stages. Its services include pharmacodynamic studies, pharmacokinetic studies, toxicology studies, and a full set of drug safety evaluation services.

Lin Changqing, Chairman of Hotgen Biotech, said that the company is continuing to deepen its dual-wheel strategy of diagnosis + treatment and strengthen the development of its innovative drug R&D system. By establishing long-term strategic cooperation with partners that have international R&D and production capabilities, the company will further accelerate the progress of key projects and improve overall R&D translation efficiency and international competitiveness.'

In the future, the three parties will take this strategic cooperation as a starting point. They will continue to explore multi-level and multi-dimensional collaborative innovation models, jointly promote the high-quality implementation of innovative achievements, and provide more accessible and affordable innovative treatment options for patients around the world.

About Hotgen Biotech

Hotgen Biotech was founded in 2005. It is a high-tech enterprise focused on the biomedical field and was listed on the STAR Market of the Shanghai Stock Exchange in September 2019 under stock code 688068.

The company continues to explore independent innovation in diagnostic technology platforms. It has established multi-omics diagnostic technology platforms covering protein biomarkers, glycan exosomes, DNA methylation, and other areas.

Its innovative technology incubation platform, the Future Technology Research Institute, focuses on exploring the transformation of frontier technologies. It has already expanded into frontier fields such as nucleic acid drugs, antibody drugs, and general health. SGC001, the globally first-in-class emergency antibody drug for myocardial infarction developed by Sungen Biomedical, has received IND approvals in both China and the United States, obtained FDA Fast Track designation, and started Phase II clinical trials.

Following its mission of Developing biotechnology to benefit human health, Hotgen Biotech is committed to building a full industrial-chain development strategy from specialized diagnostics to innovative pharmaceuticals.

About Sungen Biomedical

Sungen Biomedical is an innovation-driven biomedical technology company. It is committed to the discovery, development, and commercialization of original First-in-Class antibody drugs.

With strong scientific research and innovative drug development capabilities, the company has built a series of internationally advanced technology platforms. Guided by unmet clinical needs, it has established multiple original biologic macromolecule drug pipelines with strong market potential, covering cardiovascular and cerebrovascular diseases, tumors, and other disease areas. The company aims to improve China's new quality productive forces and benefit human health.

About JOINN Biologics

JOINN Biologics was established in early 2018 and is committed to becoming the most trusted and globally leading pharmaceutical CDMO company.

At present, the company has a core technical team of more than 400 people with rich industry experience and familiarity with Chinese and international new drug regulations. It has provided R&D and manufacturing services for about 400 macromolecular biologic drug projects and has obtained more than 50 IND approvals worldwide.

In the United States, the company has built several FDA GMP-compliant production workshops with 1000L, 500L, and 200L capacity. In China, including Beijing and Guangzhou, it has built 17 single-use macromolecular drug substance production lines with 2000L capacity that comply with international standards from China, the United States, the European Union, WHO, and others. It has also built high-end formulation workshops for lyophilized products, liquid injections, prefilled syringes, and other dosage forms.

Relying on its R&D and production bases in both China and the United States, the company will provide global innovative drug R&D institutions with one-stop solutions including developability research, process scale-up and optimization, quality research, pilot production, and commercial production.

About JOINN Laboratories

JOINN Laboratories is one of the earliest private companies in China engaged in pharmacology and toxicology evaluation of new drugs. Since its establishment in 1995, it has developed a professional technical team of nearly 2,000 people.

It is currently one of the CROs in China with the most complete qualifications and richest project experience in non-clinical drug safety evaluation. It is also one of the non-clinical CROs in China with the richest experience in supporting overseas new drug applications, including applications in the United States, Europe, Japan, South Korea, Australia, and other regions.